Related Experiment Video

Updated: Jun 1, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Developing therapeutic microRNAs for cancer

A G Bader1, D Brown, J Stoudemire

  • 1Mirna Therapeutics, Inc., Austin, TX 78744, USA. abader@mirnarx.com

Gene Therapy
|June 3, 2011
PubMed

Insights

MicroRNAs (miRNAs) offer a promising new avenue for cancer therapy by subtly repressing oncogenic gene expression. Further development focuses on drug delivery, toxicology, and regulatory pathways for these novel therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Cancer therapies face challenges including pathway disruption, drug resistance, and toxicity.
  • MicroRNAs (miRNAs) have emerged as critical regulators in cancer.
  • Novel therapeutic strategies are urgently needed to address cancer complexity.

Purpose of the Study:

  • To explore the potential of microRNAs (miRNAs) as a new class of targeted cancer therapeutics.
  • To highlight the unique mechanism of action and efficacy of miRNA-based therapies.
  • To outline the current stage of therapeutic miRNA development, including delivery and regulatory aspects.

Main Methods:

  • Review of existing evidence on the role of miRNAs in cancer.
  • Analysis of miRNA mechanism of action in gene expression regulation.
  • Examination of the developmental pipeline for therapeutic miRNAs.

Main Results:

  • miRNAs demonstrate a critical role in cancer with a unique mechanism for gene repression.
  • miRNA-based therapies are anticipated to be highly efficacious due to targeting multiple oncogenic factors.
  • Therapeutic miRNA development is progressing to pharmacological delivery, toxicology, and regulatory review.

Conclusions:

  • MicroRNAs represent a promising novel therapeutic strategy for cancer treatment.
  • The subtle gene repression mechanism of miRNAs offers potential advantages over current therapies.
  • Advancements in drug delivery and preclinical studies are crucial for the clinical translation of miRNA therapeutics.

More Related Videos

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...